{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir+400+mg&page=3",
    "query": {
      "intervention": "Raltegravir 400 mg",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 64,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir+400+mg&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir+400+mg&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T19:59:57.258Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01332227",
      "title": "Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV, Combination Therapy"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir (heat-stable)",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir/Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2011-10",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-02-19",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332227"
    },
    {
      "nct_id": "NCT00729924",
      "title": "Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-08",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-03-03",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729924"
    },
    {
      "nct_id": "NCT00802074",
      "title": "An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Fosamprenavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Garden State Infectious Disease Associates, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 45,
      "start_date": "2008-12",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "Voorhees Township, New Jersey",
      "locations": [
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802074"
    },
    {
      "nct_id": "NCT00708162",
      "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Elvitegravir",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "EVG placebo",
          "type": "DRUG"
        },
        {
          "name": "RAL placebo",
          "type": "DRUG"
        },
        {
          "name": "Background regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 724,
      "start_date": "2008-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 94,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708162"
    },
    {
      "nct_id": "NCT00654147",
      "title": "Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir & Lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir and emtricitabine/tenofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret A. Fischl, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-03",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654147"
    },
    {
      "nct_id": "NCT00672932",
      "title": "Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-04",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2013-07-05",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00672932"
    },
    {
      "nct_id": "NCT00811954",
      "title": "Comparative Study of Three NNRTI-Sparing HAART Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Emtricitabine/tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1814,
      "start_date": "2009-05",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-09-05",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811954"
    },
    {
      "nct_id": "NCT00858962",
      "title": "Buprenorphine/Raltegravir Pharmacokinetic Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-03",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858962"
    },
    {
      "nct_id": "NCT01325051",
      "title": "Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angela Kashuba, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "MALE",
        "summary": "18 Years to 49 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2011-04",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-01-05",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325051"
    },
    {
      "nct_id": "NCT01384734",
      "title": "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068 400 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 800 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 600 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2011-07-26",
      "completion_date": "2017-05-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-09T19:59:57.258Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384734"
    }
  ]
}